The Human Variable 

Infection-associated chronic conditions (IACCs), including Long COVID, ME/CFS, post-treatment Lyme disease syndrome (PTLDS), and related post-infectious syndromes, present a persistent challenge to conventional medical workflows. These conditions are multi-system, fluctuating, and temporally delayed, with symptom expression shaped by environmental exposures, autonomic regulation, immune reactivity, hormonal state, and cumulative demand.

Climate change is accelerating fungal evolution at the same moment millions of Americans are living with post-COVID immune instability. This white paper introduces CYNAERA’s national fungal-intelligence architecture, integrating climate analytics, immune-terrain modeling, wastewater genomics, micro-clinic stabilization, and antifungal combination logic. It explains why fungal threats are rising, how existing federal infrastructure can be repurposed immediately and what the Un

The Physics of Survival reframes human stability as the core infrastructure of civilization. This white paper introduces Terrain Intelligence—a unifying systems framework that links space medicine, chronic illness, and climate resilience under one predictive model. Drawing on NASA Human Research Program findings and longitudinal public-health data, Cynthia Adinig demonstrates that physiological collapse in microgravity mirrors the same autonomic and immune failure seen in Lon

Developed through over 40 failed trial reconstructions of 20+ conditions, SPARC™ decodes clinical heterogeneity using patient-derived intelligence and CYNAERA’s AI-integrated logic stacks. Each failed trial costs between $20–40 million, and in rare or stigmatized conditions, these failures permanently deter further investment. Most failed trials didn’t fail because the drug was weak. They failed because the patient groups were misread.

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio

STAIR is a structured method for helping hypersensitive patients safely prepare for new exposures: medications, supplements, clinical trials, or even food reintroductions. It’s designed specifically for bodies that traditional medicine excludes, the “too sensitive,” the “too complex,” the “we don’t know what to do with you.”